Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
about
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignanciesSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Clinical use and applications of histone deacetylase inhibitors in multiple myelomaClinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitorTreatment of relapsed and refractory multiple myelomaDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsMinimal Residual Disease Assessment in the Context of Multiple Myeloma TreatmentEvolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityEpigenetic treatment of solid tumours: a review of clinical trialsPanobinostat for the treatment of multiple myeloma: the evidence to dateAmerican Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic CeEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaThe Danish National Multiple Myeloma RegistryThe Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European PerspectiveRecent advances in understanding multiple myelomaNew investigational drugs with single-agent activity in multiple myelomaEpigenetic Therapeutics: A New Weapon in the War Against CancerRecent advances in multiple myeloma: a Korean perspectiveHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyTriplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.The next generation of novel therapies for the management of relapsed multiple myeloma.Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myelomaPanobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentQuisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Deacetylase inhibitors: an advance in myeloma therapy?Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyUpdate on the optimal use of bortezomib in the treatment of multiple myelomaSystematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.Individual patient oesophageal cancer 3D models for tailored treatment.HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cellsProteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.Phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed/refractory multiple myeloma.
P2860
Q26739689-3E11D31B-2E6C-43D8-9B6B-8A461149A3FCQ26740359-C9AB350D-7884-434F-962E-C89D8727DFB4Q26745930-15D4BF91-85D7-4A31-9409-4B6481B36E37Q26747768-B1A88D26-7160-4497-A4D8-868236880D71Q26749180-8CE08E88-3124-47BA-87E1-76FEF4683635Q26749421-D6190D26-A6C2-46E2-B6D1-A5C06664E5D7Q26768653-40702E18-0742-42F2-AC4D-919883A59AC3Q26771331-96A0DDED-3035-4198-BF91-27A21E4182F4Q26773803-459392A1-2115-4BE9-91EC-75D9CF8ACAD8Q26778674-56BD4FA3-B65A-4528-84D5-B273514F48F1Q26782868-886C683E-97C8-41D5-A7C4-E8C36B2DCED0Q27026478-CFB7120D-0841-4E58-B894-45A16D2F6E17Q28067148-27E16CF2-4445-4A13-B825-B79F2B4E7D5BQ28067187-B57E05A3-1409-4E2D-BFBB-CD6905E37E0CQ28069789-A59E3952-5895-45A6-BFC7-3FFF2510FE1CQ28070331-64D78C6F-2BAB-422E-AD13-A3A95E0EECC3Q28071551-366610B4-D3CB-42EB-87BE-F11374E0C191Q28072370-A1B25779-CF67-4399-8000-16AF513ACD61Q28074521-AB947360-AB95-4E27-8603-6ACE46A1E603Q28082536-090D7E3F-F507-4808-BA58-9A4B660EBCD8Q30238893-E42D14DA-256E-4069-BF65-3811033B1185Q30239781-7592924A-FBEC-43CB-8E6E-0B65FF17730FQ30248534-6AF2122A-7590-4227-A755-6D525B0D7114Q33423168-3AA64999-DD50-469B-9589-82E7FE427640Q33426983-8303D59C-68FA-43E6-BB64-A8F23186E8BFQ33428098-4FAB41FE-84BC-49F6-8760-28266372B544Q33429115-C0343576-F801-4CCD-B7E8-F7F8A4C4FDBCQ33432845-66658D20-2AC1-41E6-8C44-61A20EB824BBQ33437811-A873B9FA-9BD0-4030-A445-5D9CDF7F3CC3Q33438321-63D27AEC-1E43-40EA-94E4-9E66C40F514FQ33438732-FD537CB7-7597-4FB2-9CDF-E6D899E750DDQ33440007-8D841AA4-4F5C-4D65-8089-1C35978A961EQ33441476-43E369C7-3CA9-43E6-A5A2-29A9D9E6ECEBQ33443001-0866E6CC-6C5A-46ED-BA5E-501DE5040841Q33443179-31E25E6B-2038-4363-8259-B6DEB61F5BE2Q33443417-E7C4166E-FC42-48CD-AACA-D79D5F00B6FBQ33648440-9FB2CC45-0D0F-451B-9BB6-86CE8BFFE734Q33834432-BA31293C-4274-426F-8305-D398DE0D63B9Q35408665-C98A9411-327F-477F-A015-8E3817D17143Q35571044-850502D7-9B81-48DC-BEC3-6AF42F04A638
P2860
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@ast
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@en
type
label
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@ast
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@en
prefLabel
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@ast
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@en
P2093
P50
P921
P1433
P1476
Panobinostat plus bortezomib a ...... d, double-blind phase 3 trial.
@en
P2093
Andreas Günther
Bourras-Rezki Bengoudifa
Claudia Corrado
Darrell White
Florence Binlich
Jae Hoon Lee
Jamie D Cavenagh
Je-Jung Lee
Jesús F San-Miguel
P304
P356
10.1016/S1470-2045(14)70440-1
P50
P577
2014-09-18T00:00:00Z